Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
118 Results for "
Pyruvate Kinase
" in MedChemExpress (MCE) Product Catalog:
Products (118)
118 Results for "Pyruvate Kinase" in MCE Product Catalog:
Cat. No.: HY-P74629
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: PKM; Tumor M2-PK; Prev. PKM2; P58; THBP1; Thyroid Hormone-Binding Protein, Cytosolic; OIP3; Epididymis Secretory Protein Li 30; PK3; Pyruvate Kinase Isozymes M1/M2; Pyruvate Kinase Muscle Isozyme; OPA-Interacting Protein 3; Cytosolic Thyroid Hormone-Bindi
Species:
Mouse
Source:
Sf9 insect cells
Cat. No.: HY-189073
Research Areas:
Antifungal agent 175 is a potent antifungal agent with an EC50 of 1.8 μg/mL against R. solani. Antifungal agent 175 Z17 exerts its effects primarily by disrupting the cell membranes of pathogenic fungi to trigger lipid peroxidation and oxidative stress, inhibiting pyruvate kinase (PK) to interfere with energy metabolism, and binding to the cytochrome bc1 complex. Antifungal agent 175 can be used in research on rice sheath blight .
Cat. No.: HY-155936
CAS No.: 141171-14-4
Synonyms: Thymidine 5'-(α,β-imido)triphosphate
Target:
Research Areas:
dTPNPP is an α,β-iminotriphosphate analog of dTTP, with an imino group in the α,β-phosphate bridge. dTPNPP is used in studies related to nucleotide analogs and phosphoryl transfer .
Cat. No.: HY-173298
CAS No.: 2870691-38-4
Target:
Research Areas:
PDHK1-IN-2 (Compound 24) is an ATP-competitive dual inhibitor of pyruvate dehydrogenase kinases 1/2 (PDHK1/2), with an IC50 of 0.007 μM for PDHK1 and an IC50 of 0.015 μM for PDHK2. PDHK1-IN-2 can regulate immune cell metabolism and correct mitochondrial dysfunction, and is expected to be used in the research of autoimmune diseases, inflammatory diseases, cancers, and other conditions .
Cat. No.: HY-168337
CAS No.: 3052985-32-4
Target:
SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 μM and 2.97 μM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD)-related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD .
Cat. No.: HY-167832
CAS No.: 2059104-90-2
Target:
JNK SGK ROCK Tau Protein MMP DNA/RNA Synthesis Pyruvate Kinase NF-κB COX NO Synthase Reactive Oxygen Species (ROS)
Research Areas:
PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease .
Cat. No.: HY-DY1120
Target:
Research Areas:
ZY-2 (solution) is a fluorescent probe targeting pyruvate kinase M2 (PKM2) with an excitation wavelength of 419 nm. ZY-2 (solution) significantly activates purified PKM2 protein. ZY-2 (solution) exhibits enhanced fluorescence emission in low-polarity or high-viscosity environments. ZY-2 (solution) enables highly sensitive and selective fluorescence imaging of PKM2 in live PKM2-positive cancer cells, with no significant side effects on cell viability within its effective concentration range. ZY-2 (solution) can be used for cervical cancer research .
Solvent and concentration: DMSO: 10 mM
Solvent and concentration: DMSO: 10 mM
Cat. No.: HY-178441
Research Areas:
PKM2-IN-11 is a PKM2 inhibitor (IC50 = 0.363 μM). PKM2-IN-11 has dual mechanisms involving pyruvate kinase M2 (PKM2) inhibition and microtubule stabilization. PKM2-IN-11 can decrease PKM2 protein levels in MCF-7 cells. PKM2-IN-11 can slightly reduce reactive oxygen species (ROS) levels and significantly increase early apoptotic cells. PKM2-IN-11 induces G2/M phase arrest. PKM2-IN-11 can be used for the study of breast cancer .
Target:
Pyruvate Kinase COX STAT TNF Receptor NO Synthase Interleukin Related HIF/HIF Prolyl-Hydroxylase
Research Areas:
Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases .
Cat. No.: HY-W753956
CAS No.: 3044090-39-0
Cat. No.: HY-172285
CAS No.: 871514-32-8
Cat. No.: HY-172285A
Cat. No.: HY-183765
Target:
Research Areas:
PARP1/PKM2-IN-1 is a dual PARP1/PKM2 inhibitor, with an IC50 of 39.5 nM against PARP1, and IC50 values of 261 nM (recombinant PKM2) and 50 nM (dimeric PKM2) against PKM2. PARP1/PKM2-IN-1 reduces the dimerization of PKM2 and decreases its nuclear accumulation level. PARP1/PKM2-IN-1 also selectively downregulates PKM2 mRNA and impairs poly (ADP-ribose)-mediated nuclear retention of PKM2. PARP1/PKM2-IN-1 exhibits antiproliferative activity and inhibits the formation of 3D cancer spheroids. PARP1/PKM2-IN-1 can be used in research related to mammary adenocarcinoma, triple-negative breast cancer, BRCA1-mutant triple-negative breast cancer, and prostate adenocarcinoma .
Cat. No.: HY-W004643
CAS No.: 13114-72-2
Synonyms: AK-II
Research Areas:
Akardite II (AK-II) is a stabilizer for nitrocellulose (NC) propellants that scavenges NOx. Akardite II is used in research related to the identification of organic compounds in gunpowder .
Cat. No.: HY-112253
CAS No.: 15978-08-2
Target:
Target:
PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 SnRK
Research Areas:
RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC. RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
